Aktienanalyse zu Bio-Techne Corp (TECH)TECHBio-Techne Corp

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Bio-Techne Corp is currently trading at $72.46, which is just below the analyst price target of $73. The company's recent quarterly earnings showed a net profit of $54.622 million, a significant recovery from a loss in the same quarter last year, indicating strong operational improvement. However, insider selling has increased by 174.32% and hedge fund selling by 5004.01%, which raises concerns about confidence in the stock. The RSI is at 49.404, suggesting the stock is neither overbought nor oversold, indicating a neutral technical stance. Given these factors, it may be prudent to hold rather than buy at this time, especially with the potential acquisition by Merck KGaA looming, which could affect future price movements.

9 analysts cover TECH: 6 rate it Buy, 3 Hold and 0 Sell. The average price target is 66.14.